Sökning: WFRF:(Fagerli K.) > Effectiveness and t...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05440naa a2200733 4500 | |
001 | oai:gup.ub.gu.se/307345 | |
003 | SwePub | |
008 | 240910s2021 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:147964747 | |
024 | 7 | a https://gup.ub.gu.se/publication/3073452 URI |
024 | 7 | a https://doi.org/10.1136/annrheumdis-2021-2200972 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1479647472 URI |
040 | a (SwePub)gud (SwePub)ki | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Lindström, Ulfu Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut0 (Swepub:gu)xlulfn |
245 | 1 0 | a Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration |
264 | c 2021-06-03 | |
264 | 1 | b BMJ,c 2021 |
520 | a Background: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy. Methods: Patients with PsA from 13 European countries who initiated a first TNFi in 2006-2017 were included. Country-specific comparisons of 1 year TNFi retention were performed by csDMARD comedication status, together with HRs for TNFi discontinuation (comedication vs monotherapy), adjusted for age, sex, calendar year, disease duration and Disease Activity Score with 28 joints (DAS28). Adjusted ORs of clinical remission (based on DAS28) at 12 months were calculated. Between-country heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Secondary analyses stratified according to TNFi subtype (adalimumab/infliximab/etanercept) and restricted to methotrexate as comedication were performed. Results: In total, 15 332 patients were included (62% comedication, 38% monotherapy). TNFi retention varied across countries, with significant heterogeneity precluding a combined estimate. Comedication was associated with better remission rates, pooled OR 1.25 (1.12-1.41). Methotrexate comedication was associated with improved remission for adalimumab (OR 1.45 (1.23-1.72)) and infliximab (OR 1.55 (1.21-1.98)) and improved retention for infliximab. No effect of comedication was demonstrated for etanercept. Conclusion: This large observational study suggests that, as used in clinical practice, csDMARD and TNFi comedication are associated with improved remission rates, and specifically, comedication with methotrexate increases remission rates for both adalimumab and infliximab. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng |
653 | a arthritis | |
653 | a methotrexate | |
653 | a psoriatic | |
653 | a tumour necrosis factor inhibitors | |
700 | 1 | a Di Giuseppe, D.u Karolinska Institutet4 aut |
700 | 1 | a Delcoigne, B.u Karolinska Institutet4 aut |
700 | 1 | a Glintborg, B.4 aut |
700 | 1 | a Möller, B.4 aut |
700 | 1 | a Ciurea, A.4 aut |
700 | 1 | a Pombo-Suarez, M.4 aut |
700 | 1 | a Sanchez-Piedra, C.4 aut |
700 | 1 | a Eklund, K.4 aut |
700 | 1 | a Relas, H.4 aut |
700 | 1 | a Gudbjornsson, B.4 aut |
700 | 1 | a Love, T. J.4 aut |
700 | 1 | a Jones, G. T.4 aut |
700 | 1 | a Codreanu, C.4 aut |
700 | 1 | a Ionescu, R.4 aut |
700 | 1 | a Nekvindova, L.4 aut |
700 | 1 | a Závada, J.4 aut |
700 | 1 | a Atas, N.4 aut |
700 | 1 | a Yolbas, S.4 aut |
700 | 1 | a Fagerli, K. M.4 aut |
700 | 1 | a Michelsen, B.4 aut |
700 | 1 | a Rotar,, Rotar,4 aut |
700 | 1 | a Tomšič, M.4 aut |
700 | 1 | a Iannone, F.4 aut |
700 | 1 | a Santos, M. J.4 aut |
700 | 1 | a Avila-Ribeiro, P.4 aut |
700 | 1 | a Ørnbjerg, L. M.4 aut |
700 | 1 | a Østergaard, M.4 aut |
700 | 1 | a Jacobsson, Lennart T. H.,d 1954u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut0 (Swepub:gu)xjacle |
700 | 1 | a Askling, J.u Karolinska Institutet4 aut |
700 | 1 | a Nissen, M. J.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning4 org |
773 | 0 | t Annals of the Rheumatic Diseasesd : BMJg 80, s. 1410-1418q 80<1410-1418x 0003-4967x 1468-2060 |
856 | 4 | u https://ard.bmj.com/content/annrheumdis/early/2021/06/14/annrheumdis-2021-220097.full.pdf |
856 | 4 8 | u https://gup.ub.gu.se/publication/307345 |
856 | 4 8 | u https://doi.org/10.1136/annrheumdis-2021-220097 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:147964747 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.